LVEF during SB without ectopy and SB post-PVC at 200 and 350 ms coupling intervals before (baseline) and after the development of PVC-CM (Week 12 bigeminal PVCs)
. | Baseline . | Final (Week 12) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
. | No PVCs (Echo-1) . | CI: 200 ms (Echo–2) . | CI: 350 ms (Echo-3) . | No PVCs (Echo-1) . | CI: 200 ms (Echo-2) . | CI: 350 ms (Echo-3) . | ||||
Animal . | SB LVEF . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB LVEF . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB post-PVC LVEF . | PESP LVEF (delta) . |
1 | 62 | 84 | 22 | 70 | 8 | 46 | 66 | 20 | 57 | 11 |
2 | 67 | 72 | 5 | 69 | 2 | 38 | 70 | 32 | 72 | 34 |
3 | 68 | 70 | 2 | 68 | 0 | 37 | 66 | 29 | 64 | 27 |
4 | 60 | 65 | 5 | 62 | 2 | 40 | 60 | 20 | 50 | 10 |
5 | 68 | 76 | 8 | 66 | −2 | 33 | 68 | 35 | 66 | 33 |
6 | 60 | 82 | 22 | 62 | 2 | 51 | 58 | 7 | 49 | −2 |
7 | 65 | 70 | 5 | 66 | 1 | 28 | 72 | 44 | 63 | 35 |
8 | 55 | 76 | 21 | 58 | 3 | 48 | 61 | 13 | 62 | 14 |
9 | 55 | 68 | 13 | 62 | 7 | 42 | 76 | 34 | 62 | 20 |
10 | 63 | 75 | 12 | 68 | 5 | 48 | 54 | 6 | 55 | 7 |
11 | 60 | 80 | 20 | 62 | 2 | 46 | 52 | 6 | 62 | 16 |
Mean | 62.1 ± 4.6 | 74.4 ± 6 | 12.3 ± 7.8* | 64.8 ± 3.8 | 2.7 ± 2.9 | 41.5 ± 7.1 | 63.9 ± 7.6 | 22.4 ± 13.3* | 60.2 ± 6.9 | 18.6 ± 12.3* |
R = 0.8, P = 0.003 | R = 0.54 P = 0.09 | R = −0.9, P < 0.001 | R = −0.88, P < 0.001 |
. | Baseline . | Final (Week 12) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
. | No PVCs (Echo-1) . | CI: 200 ms (Echo–2) . | CI: 350 ms (Echo-3) . | No PVCs (Echo-1) . | CI: 200 ms (Echo-2) . | CI: 350 ms (Echo-3) . | ||||
Animal . | SB LVEF . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB LVEF . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB post-PVC LVEF . | PESP LVEF (delta) . |
1 | 62 | 84 | 22 | 70 | 8 | 46 | 66 | 20 | 57 | 11 |
2 | 67 | 72 | 5 | 69 | 2 | 38 | 70 | 32 | 72 | 34 |
3 | 68 | 70 | 2 | 68 | 0 | 37 | 66 | 29 | 64 | 27 |
4 | 60 | 65 | 5 | 62 | 2 | 40 | 60 | 20 | 50 | 10 |
5 | 68 | 76 | 8 | 66 | −2 | 33 | 68 | 35 | 66 | 33 |
6 | 60 | 82 | 22 | 62 | 2 | 51 | 58 | 7 | 49 | −2 |
7 | 65 | 70 | 5 | 66 | 1 | 28 | 72 | 44 | 63 | 35 |
8 | 55 | 76 | 21 | 58 | 3 | 48 | 61 | 13 | 62 | 14 |
9 | 55 | 68 | 13 | 62 | 7 | 42 | 76 | 34 | 62 | 20 |
10 | 63 | 75 | 12 | 68 | 5 | 48 | 54 | 6 | 55 | 7 |
11 | 60 | 80 | 20 | 62 | 2 | 46 | 52 | 6 | 62 | 16 |
Mean | 62.1 ± 4.6 | 74.4 ± 6 | 12.3 ± 7.8* | 64.8 ± 3.8 | 2.7 ± 2.9 | 41.5 ± 7.1 | 63.9 ± 7.6 | 22.4 ± 13.3* | 60.2 ± 6.9 | 18.6 ± 12.3* |
R = 0.8, P = 0.003 | R = 0.54 P = 0.09 | R = −0.9, P < 0.001 | R = −0.88, P < 0.001 |
PESP LVEF (%) = SB post-PVC LVEF (%) − SB LVEF without ectopy (%); correlation coefficient (Pearson, R) between PESP LVEF at 200 ms/350 ms and final LVEF.
CI, coupling interval; CM, cardiomyopathy; LVEF, left ventricular ejection fraction; PESP, post-extrasystolic potentiation; PVC, premature ventricular contraction; SB, sinus beat. *P value <0.05
LVEF during SB without ectopy and SB post-PVC at 200 and 350 ms coupling intervals before (baseline) and after the development of PVC-CM (Week 12 bigeminal PVCs)
. | Baseline . | Final (Week 12) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
. | No PVCs (Echo-1) . | CI: 200 ms (Echo–2) . | CI: 350 ms (Echo-3) . | No PVCs (Echo-1) . | CI: 200 ms (Echo-2) . | CI: 350 ms (Echo-3) . | ||||
Animal . | SB LVEF . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB LVEF . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB post-PVC LVEF . | PESP LVEF (delta) . |
1 | 62 | 84 | 22 | 70 | 8 | 46 | 66 | 20 | 57 | 11 |
2 | 67 | 72 | 5 | 69 | 2 | 38 | 70 | 32 | 72 | 34 |
3 | 68 | 70 | 2 | 68 | 0 | 37 | 66 | 29 | 64 | 27 |
4 | 60 | 65 | 5 | 62 | 2 | 40 | 60 | 20 | 50 | 10 |
5 | 68 | 76 | 8 | 66 | −2 | 33 | 68 | 35 | 66 | 33 |
6 | 60 | 82 | 22 | 62 | 2 | 51 | 58 | 7 | 49 | −2 |
7 | 65 | 70 | 5 | 66 | 1 | 28 | 72 | 44 | 63 | 35 |
8 | 55 | 76 | 21 | 58 | 3 | 48 | 61 | 13 | 62 | 14 |
9 | 55 | 68 | 13 | 62 | 7 | 42 | 76 | 34 | 62 | 20 |
10 | 63 | 75 | 12 | 68 | 5 | 48 | 54 | 6 | 55 | 7 |
11 | 60 | 80 | 20 | 62 | 2 | 46 | 52 | 6 | 62 | 16 |
Mean | 62.1 ± 4.6 | 74.4 ± 6 | 12.3 ± 7.8* | 64.8 ± 3.8 | 2.7 ± 2.9 | 41.5 ± 7.1 | 63.9 ± 7.6 | 22.4 ± 13.3* | 60.2 ± 6.9 | 18.6 ± 12.3* |
R = 0.8, P = 0.003 | R = 0.54 P = 0.09 | R = −0.9, P < 0.001 | R = −0.88, P < 0.001 |
. | Baseline . | Final (Week 12) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
. | No PVCs (Echo-1) . | CI: 200 ms (Echo–2) . | CI: 350 ms (Echo-3) . | No PVCs (Echo-1) . | CI: 200 ms (Echo-2) . | CI: 350 ms (Echo-3) . | ||||
Animal . | SB LVEF . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB LVEF . | SB post-PVC LVEF . | PESP LVEF (delta) . | SB post-PVC LVEF . | PESP LVEF (delta) . |
1 | 62 | 84 | 22 | 70 | 8 | 46 | 66 | 20 | 57 | 11 |
2 | 67 | 72 | 5 | 69 | 2 | 38 | 70 | 32 | 72 | 34 |
3 | 68 | 70 | 2 | 68 | 0 | 37 | 66 | 29 | 64 | 27 |
4 | 60 | 65 | 5 | 62 | 2 | 40 | 60 | 20 | 50 | 10 |
5 | 68 | 76 | 8 | 66 | −2 | 33 | 68 | 35 | 66 | 33 |
6 | 60 | 82 | 22 | 62 | 2 | 51 | 58 | 7 | 49 | −2 |
7 | 65 | 70 | 5 | 66 | 1 | 28 | 72 | 44 | 63 | 35 |
8 | 55 | 76 | 21 | 58 | 3 | 48 | 61 | 13 | 62 | 14 |
9 | 55 | 68 | 13 | 62 | 7 | 42 | 76 | 34 | 62 | 20 |
10 | 63 | 75 | 12 | 68 | 5 | 48 | 54 | 6 | 55 | 7 |
11 | 60 | 80 | 20 | 62 | 2 | 46 | 52 | 6 | 62 | 16 |
Mean | 62.1 ± 4.6 | 74.4 ± 6 | 12.3 ± 7.8* | 64.8 ± 3.8 | 2.7 ± 2.9 | 41.5 ± 7.1 | 63.9 ± 7.6 | 22.4 ± 13.3* | 60.2 ± 6.9 | 18.6 ± 12.3* |
R = 0.8, P = 0.003 | R = 0.54 P = 0.09 | R = −0.9, P < 0.001 | R = −0.88, P < 0.001 |
PESP LVEF (%) = SB post-PVC LVEF (%) − SB LVEF without ectopy (%); correlation coefficient (Pearson, R) between PESP LVEF at 200 ms/350 ms and final LVEF.
CI, coupling interval; CM, cardiomyopathy; LVEF, left ventricular ejection fraction; PESP, post-extrasystolic potentiation; PVC, premature ventricular contraction; SB, sinus beat. *P value <0.05
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.